Near-term catalyst remains the Phase 2 data readouts (HS Q4 2026, SSc 1H 2027). The EPS miss was modest for a pre-revenue biotech and the strong cash runway removes near-term financing risk. Monitor for any trial enrollment updates or competitive landscape changes.
Price Chart
Executive Summary
Zura Bio reported Q1 2026 net loss of $24.2M ($0.22/share), wider than consensus estimate of -$0.17 and the year-ago loss of $17.4M ($0.19). Cash stood at $225.6M, expected to fund operations through at least end-2028. No revenue or guidance was provided; clinical progress remains on track with Phase 2 data readouts anticipated in Q4 2026 and 1H 2027.
Key Financial Metrics
Key Facts
- Q1 2026 net loss of $24.2M ($0.22 per share) vs consensus of -$0.17 and prior year loss of $17.4M ($0.19)
- Cash and cash equivalents $225.6M as of March 31, 2026, up from $109.4M at year-end 2025 after $144M public offering in February 2026
- R&D expenses increased to $14.7M from $10.5M year-over-year, driven by Phase 2 tibulizumab programs
- Phase 2 TibuSHIELD (HS) and TibuSURE (SSc) trials on track for topline data in Q4 2026 and 1H 2027 respectively
- No revenue, no approved products, no guidance provided
Financial Impact
Net loss widened by $6.8M vs prior year; cash position strengthened by $116.2M from public offering
Risk Factors
- Phase 2 clinical failure in HS or SSc
- Cash burn may require additional financing if trials extend beyond current runway
- Competitive IL-17/BAFF programs from larger players
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-031701 |
| Document: corporatedeck_zurabiox07.htm | 0001628280-26-031701 |
| Document: zura-20260507.htm | 0001628280-26-031701 |
| Document: 0001628280-26-031701-index-headers.html | 0001628280-26-031701 |
| Document: 0001628280-26-031701-index.html | 0001628280-26-031701 |
| Document: 0001628280-26-031701.txt | 0001628280-26-031701 |
| 8-K Data (Synthetic) | 0001628280-26-031701 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 17, 2026 10w ago | 8-K | $5.68 $4.93 | ▼ −13.20% | ▼ −11.23% | $3.56 (−37.32%) |
Aug 11, 2026 10w ago | 8-K | $5.56 $5.71 | ▲ +2.70% | ▲ +3.76% | $3.56 (−35.97%) |
Jul 1, 2026 16w ago | 8-K | $5.01 $5.31 | ▲ +6.09% | ▲ +8.28% | $3.56 (−28.87%) |
Jun 18, 2026 18w ago | 8-K | $4.23 $5.45 | ▲ +28.84% | ▲ +28.99% | $3.56 (−15.84%) |
May 7, 2026 24w ago | 8-K | $4.54 $3.86 | ▼ −14.98% | ▼ −18.11% | $3.56 (−21.59%) |
Mar 5, 2026 33w ago | 8-K | $6.76 $6.03 | ▼ −10.80% | ▼ −7.01% | $3.56 (−47.34%) |
Feb 26, 2026 34w ago | 8-K | $6.77 $6.04 | ▼ −10.78% | ▼ −4.38% | $3.56 (−47.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers